Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

Neoadjuvant endocrine therapy with an aromatase inhibitor has shown efficacy comparable to that of neoadjuvant chemotherapy in patients with postmenopausal breast cancer. Preclinical and clinical studies have shown that the antidiabetic drug metformin has anti-tumor activity. This prospective, multi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2014-03, Vol.14 (1), p.170-170, Article 170
Hauptverfasser:	Kim, Jisun, Lim, Woosung, Kim, Eun-Kyu, Kim, Min-Kyoon, Paik, Nam-Sun, Jeong, Sang-Seol, Yoon, Jung-Han, Park, Chan Heun, Ahn, Sei Hyun, Kim, Lee Su, Han, Sehwan, Nam, Seok Jin, Kang, Han-Sung, Kim, Seung Il, Yoo, Young Bum, Jeong, Joon, Kim, Tae Hyun, Kang, Taewoo, Kim, Sung-Won, Jung, Yongsik, Lee, Jeong Eon, Kim, Ku Sang, Yu, Jong-Han, Chae, Byung Joo, Jung, So-Youn, Kang, Eunyoung, Choi, Su Yun, Moon, Hyeong-Gon, Noh, Dong-Young, Han, Wonshik
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Chemotherapy Clinical Protocols Colleges & universities Female Hospitals Humans Insulin-like growth factors Medical research Metformin - administration & dosage Neoadjuvant Therapy Nitriles - administration & dosage Postmenopause Receptors, Estrogen - metabolism Research Design Study Protocol Triazoles - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!